A detailed history of Bank Of Montreal transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Bank Of Montreal holds 39,585 shares of PCRX stock, worth $694,716. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39,585
Previous 22,825 73.43%
Holding current value
$694,716
Previous $653,000 8.73%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$11.7 - $28.46 $196,092 - $476,989
16,760 Added 73.43%
39,585 $596,000
Q2 2024

Aug 14, 2024

BUY
$25.5 - $31.51 $455,991 - $563,461
17,882 Added 361.76%
22,825 $653,000
Q1 2024

May 13, 2024

SELL
$27.7 - $35.48 $57,477 - $73,621
-2,075 Reduced 29.57%
4,943 $144,000
Q4 2023

Feb 08, 2024

BUY
$26.32 - $34.31 $21,977 - $28,648
835 Added 13.5%
7,018 $236,000
Q3 2023

Nov 01, 2023

BUY
$30.68 - $40.09 $19,880 - $25,978
648 Added 11.71%
6,183 $189,000
Q2 2023

Aug 02, 2023

BUY
$36.12 - $47.5 $51,037 - $67,117
1,413 Added 34.28%
5,535 $221,000
Q1 2023

Jun 13, 2024

BUY
$35.53 - $43.38 $63,314 - $77,303
1,782 Added 36.05%
6,725 $274,000
Q4 2022

Feb 01, 2023

SELL
$38.19 - $57.45 $32,155 - $48,372
-842 Reduced 16.96%
4,122 $159,000
Q3 2022

Nov 10, 2022

BUY
$51.24 - $58.89 $13,886 - $15,959
271 Added 5.77%
4,964 $270,000
Q2 2022

Aug 11, 2022

SELL
$51.49 - $81.64 $385,608 - $611,401
-7,489 Reduced 61.48%
4,693 $272,000
Q1 2022

May 12, 2022

BUY
$60.03 - $76.49 $8,164 - $10,402
136 Added 1.13%
12,182 $929,000
Q4 2021

Feb 11, 2022

SELL
$47.97 - $62.21 $151,825 - $196,894
-3,165 Reduced 20.81%
12,046 $753,000
Q3 2021

Nov 12, 2021

SELL
$54.64 - $61.3 $14,206 - $15,938
-260 Reduced 1.68%
15,211 $863,000
Q2 2021

Aug 12, 2021

BUY
$59.18 - $69.99 $915,573 - $1.08 Million
15,471 New
15,471 $964,000

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $804M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Bank Of Montreal Portfolio

Follow Bank Of Montreal and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.